Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/19/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong William Oh?

William K. Oh

Chief, Division of Hematology and Medical Oncology

Mount Sinai School of Medicine

HQ Phone:  (212) 241-6500

Direct Phone: (212) ***-****direct phone

Email: w***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Mount Sinai School of Medicine

Box 1497 , One Gustave L. Levy Place

New York City, New York,10029

United States

Company Description

Located in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Si... more

Find other employees at this company (7,545)

Background Information

Employment History

Director

Dana-Farber Cancer Institute


Associate Director of Clinical Research

The Tisch Cancer Institute


Affiliations

Oncology Congress

Advisory Board Member


Prostate Awareness Research Foundation

Scientific Advisory Board Member


Genitourinary Committee of Cancer and Leukemia Group B

Core Member


American Society of Clinical Oncology

Cancer Education Committee


Education

B.S.

Yale University


M.D.

Dana Farber Cancer Institute


M.D.

Harvard Medical School


M.D.

New York University School of Medicine


MD

The Tisch Cancer Institute


Web References(109 Total References)


www.checkpointsciences.com

William K. Oh, MD
Science Advisory Board William K. Oh, MD William K. Oh, MD Chief Scientific Officer and Chairman of the Science Advisory Board Dr. William Oh is the Chief of the Division of Hematology and Medical Oncology at Mount Sinai Hospital in New York City; Professor of Medicine and Urology and Ezra M. Greenspan Professor in Clinical Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai; and Associate Director for Clinical Research at The Tisch Cancer Institute at Mount Sinai. Dr. Oh is an internationally recognized expert in the management of genitourinary (GU) malignancies (including prostate, renal, bladder and testicular cancers) and in using biological data banks to advance the understanding of cancer and cancer treatment. Dr. Oh's research interests include the role of chemotherapy and novel therapeutics in advanced prostate cancer. A leading investigator in the use of neoadjuvant chemotherapy in men with high-risk localized prostate cancer, he has served as the principal investigator of multiple clinical trials in prostate and other GU cancers. Before joining Mount Sinai, Dr. Oh was an attending physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, both in Boston, Massachusetts. Dr. Oh became a national leader in developing clinical trials examining neoadjuvant chemotherapy in men with high-risk localized prostate cancer as well as in studying the role of platinum chemotherapy in castration-resistant prostate cancer. At Dana-Farber, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and Director of the Gelb Center for Translational Research and was the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. There, he developed a large clinical database and specimen repository for GU cancers that enrolled more than 8,000 patients with prostate, renal and bladder cancer. Dr. Oh has been inducted into the American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors. Dr. Oh has published more than 250 original articles, reviews and book chapters (click here) on topics relating to prostate, renal, bladder and testicular cancers. He has edited three books on prostate cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer. Dr. Oh co-edits "Testicular Cancer" for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He also serves on the editorial boards of Clinical Genitourinary Cancer and American Journal of Hematology and Oncology. Dr. Oh received a B.S. from Yale University and obtained his medical degree from New York University School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute. Media Links Dr. Oh discusses risk factors for prostate cancer. Dr. Oh discusses reducing prostate cancer risk. Dr. Oh discussesPSA tests and false positives. Dr. Oh discusses the symptoms of prostate cancer. Dr. Oh discusses prostate cancer monitoring. Dr. Oh discusses treatment options for prostate cancer. Dr. Oh discusses what to ask about prostate cancer. Dr. Oh discusses advanced prostate cancer and making the most of doctor appointments. Dr. Oh discusses combination studies in prostate cancer. Dr. Oh discusses the place of novel agents focused on the androgen axis at the 2013 ASCO meeting. Dr. Oh discusses various issues in metastatic castration resistant prostate cancer.


www.checkpointsciences.com

William K. Oh, MD
Science Advisory Board William K. Oh, MD William K. Oh, Chief Scientific Officer and Chairman of the Science Advisory Board Dr. William Oh is the Chief of the Division of Hematology and Medical Oncology at Mount Sinai Hospital in New York City; Professor of Medicine and Urology and Ezra M. Greenspan Professor in Clinical Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai; and Associate Director for Clinical Research at The Tisch Cancer Institute at Mount Sinai.


www.checkpointsciences.com

William K. Oh, MD
Science Advisory Board William K. Oh, MD William K. Oh, MD, Chief Scientific Officer and Chairman of the Science Advisory Board Dr. William Oh is the Chief of the Division of Hematology and Medical Oncology at Mount Sinai Hospital in New York City; Professor of Medicine and Urology and Ezra M. Greenspan Professor in Clinical Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai; and Associate Director for Clinical Research at The Tisch Cancer Institute at Mount Sinai.


www.grandroundsinurology.com

William K. Oh, MD
William K. Oh, MD Icahn School of Medicine at Mount Sinai William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute. [su_spacer] Dr. Oh's research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer. [su_spacer] His major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. [su_spacer] Dr. Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana-Farber Cancer Institute. [su_spacer] From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine. [su_spacer] Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA - A Cancer Journal for Clinicians. [su_spacer]


www.grandroundsinurology.com [cached]

William K. Oh, MD
Dr. William K. Oh spoke at the 21st annual Scottsdale Prostate Cancer Symposium 2016 on Saturday, March 12, 2016 on "Chemotherapy for High Risk Localized Prostate Cancer?". PresentationAbout the AuthorReferencesKeywordsCite View Full Screen in New Window Dr. Oh William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute. Dr. Oh's research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer. His major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. Dr. Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana-Farber Cancer Institute. From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine. Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA - A Cancer Journal for Clinicians. Oh has been the principal investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients. N/A locally advanced prostate cancer, chemotherapy, neoadjuvant therapy, radical prostatectomy How to cite: Oh, William K. "Chemotherapy for High Risk Localized Prostate Cancer? Grand Rounds in Urology. March 12, 2016. Accessed April 17, 2017. http://www.grandroundsinurology.com/prostate-cancer-william-k-oh-chemotherapy-for-high-risk-localized-prostate-cancer/.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory